The Challenges of FMD Vaccine Production
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Old Road Campus
Old Road Campus 4a, 4b, 4c, U5 n o t Oxford City Centre g OLD ROAD n i d 4a, 4b, 4c, U5 a e H K O L L A D R O W AD E M I L 4,4a,4b,4c, U1X,U5 A41 42 4,4a,4b,4c,U5 Rin D 4 g R oad 6 7 1 13 3 11 C H U R C H I L L 900 D 2 R I 700, 900 V E E O x f o 5 A C rd 12 C i ty 10 C e n t re B 8 CAR PARK C 9 h u r c R F h i O l l O S H E o V s N E p L i T t DRI a VE ENTRANCE ROOSEVELT DRIVE l 900, ST2 Index 1 The Triangle Nursery 9 Old Road Campus Estates Annexe 13 Boundary Brook House Interserve Joint Research Office Kennedy Institute 2 - Research Services, Medical Sciences Division Old Road Campus Research Building 10 - Clinical Trials and Research Governance 3 New Richards Building Department of Oncology - Human Tissue Governance CRUK/MRC Oxford Institute for Radiation Oncology - Medical Sciences Division Business Development 4 NDM Research Building Institute of Biomedical Engineering Nuffield Department of Primary Care Health Sciences Target Discovery Institute Jenner Institute Medical Sciences Divisional Safety Officers Centre for Tropical Medicine and Global Health Bodleian Knowledge Centre (Library Services) Medical Sciences Division IT Services 5 Wellcome Centre for Human Genetics (WHG) Ludwig Institute for Cancer Research Structural Genomics Consortium 6 Henry Wellcome Building for Molecular Physiology Nuffield Department of Surgical Sciences Loading Bays and Delivery Offices of the Nuffield Professor of Medicine ENTRANCE VIA BUILDING 5 11 Big Data Institute A Wellcome Trust Centre for Human Genetics 7 Henry Wellcome Building for Particle Imaging -
On Sustainable and Climate Change Adapted Land Use in the Mongolian Crop Sector
STUDY ON SUSTAINABLE AND CLIMATE CHANGE ADAPTED LAND USE IN THE MONGOLIAN CROP SECTOR ULAANBAATAR 2020 STUDY ON SUSTAINABLE AND CLIMATE CHANGE ADAPTED LAND USE IN THE MONGOLIAN CROP SECTOR Implemented by THE GERMAN-MONGOLIAN COOPERATION PROJECT ON SUSTAINABLE AGRICULTURE STUDY ON SUSTAINABLE AND CLIMATE CHANGE ADAPTED LAND USE IN THE MONGOLIAN CROP SECTOR Disclaimer CONTENTS This study is published under the responsibility of German-Mongolian FOREWORDS ii Cooperation Project Sustainable Agriculture (MNG 19-01) and Subproject Expert dialogue on agriculture for climate change adaptation of the Mongolian LIST OF ABBREVIATIONS viii crop sector (MNG 19-02), which are funded by the German Federal Ministry of Food and Agriculture (BMEL). All views and results, conclusions, proposals or 1. THE EFFECTS OF CLIMATE CHANGE ON THE CROP FARMING recommendations stated therein are the property of the authors and do not SECTOR OF MONGOLIA necessarily reflect the opinion of the BMEL. Natsagdorj L., Erdenetsetseg B. 1 2. TECHNOLOGICAL SOLUTIONS FOR CLIMATE CHANGE ADAPTED FARMING Gantulga G., Odgerel B., Bayarmaa Kh., Ganbaatar B., Nyambayar B., Tsogtsaran B. 31 3. OPTIMIZING HUMUS, WATER, AND NUTRIENT MANAGEMENT IN MONGOLIA IN CHANGING CLIMATE CONDITIONS Guggenberger G. 75 4. SUSTAINABLE FARMING ALTERNATIVES IN MONGOLIA UNDER CHANGING CLIMATE CONDITIONS Meinel T. 114 5. ASSESSMENT OF CLIMATE CHANGE IMPACTS ON THE ARABLE FARMING SECTOR OF MONGOLIA Modelling of expected yield developments in spring wheat and potato production Noleppa S., Hackenberg I. 160 Edited by: Prof. Dr. G.Gantulga 6. INDEX-BASED CROP INSURANCE: INTERNATIONAL EXPERIENCE AND OPPORTUNITIES FOR MONGOLIA Dr. B.Erdenebolor Kuhn L., Bobojonov I. 222 7. MONGOLIA’S POLICIES AND INSTITUTIONAL APPROACHES FOR CLIMATE CHANGE ADAPTATION IN CROP FARMING Dagvadojr D. -
Astrazeneca-Oxford Vaccine Approved for Use in the U.K
P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe. -
Annual Meeting
Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign. -
Jenner Institute Complementary Vaccines Platform Technologies
WHO R&D Blueprint: Janssen Vaccines – Jenner Institute complementary Vaccines Platform Technologies Janssen Vaccines: Jenner Institute: Olga Popova Prof. Sarah Gilbert Jerome Custers WHO Geneva, 21 July 2016 Background • Jenner Institute & Janssen Vaccines presented respective proposals to WHO R&D Blueprint Workshop in April 2016, and were invited to join forces for Round 2 submission • Example of alignment, coordination and partnership between public and private sector stakeholders • Understanding nature of vaccine development, established complementary end‐to‐end skills and capabilities • Long‐term, sustainable & consistent approach and funding • High‐level flexible proposal with illustrative examples • «Bona fide»: collaborative framework to be developed JOINTLY TOWARDS TANGIBLE OUTCOMES x GLOBAL PUBLIC HEALTH 2 Success factors • Available platforms and previous experience with pathogens • Ability to invest time and resources, leverage expertise, minimise opportunity costs and ensure business continuity • Appropriate and functionable operational model, speed • Lean governance, partner alignment and milestone orientation INTERNAL • Reliable & qualified partners, durable commitments • Long‐term reliable funding (min 5‐year horizon) • Resolving vaccination indemnification / liability issue • Consistency in pathogen prioritisation and defined, consistent pre‐ established endpoint commitment • Clear and accelerated / streamlined regulatory pathways, conditions & predictability of licensure EXTERNAL • Anticipated deployment plans and community -
1 Degradation in Mongolia's Gobi Desert: Not As Straight Forward As
Degradation in Mongolia’s Gobi Desert: not as straight forward as assumed J. Addison A,B . M. Friedel A. C. Brown C. J. Davies A. S. Waldron A. A c /o CSIRO Ecosystem Sciences, PO Box 2111, Alice Springs, NT, 0871, Australia B Corresponding author: [email protected] C School of Agriculture and Food Science, University of Queensland, St Lucia, Qld, 4067, Australia Short title: How applicable are degradation assumptions to Mongolia’s Gobi Desert? Abstract Assumptions about the levels and causes of rangeland degradation in Mongolia have become embedded amongst a range of stakeholders. This paper explores the applicability of five such widely-held assumptions about rangeland degradation in Mongolia to the more specific case of the rangelands of the Gobi Desert. These assumptions are: i) there are too many animals; ii) goats have proportionally increased and this is causing desertification; iii) rainfall is declining; iv) there is less pasture now; and v) Mongolian rangelands are degraded. Biophysical and quantitative social data from the Dundgobi and Omnogobi desert-steppe areas suggest not all of these assumptions are supported mechanistically all of the time, and that the information upon which these assumptions are based is more complex than is commonly recognised. Caution in designing policy and programmes based on current understandings of rangeland condition is necessary. 1 Additional keywords : rangeland, Gobi Desert, livestock, goats, climate Introduction Rangeland theory and the understanding of causal mechanisms behind rangeland dynamics have changed significantly over the last century. The largely static ‘climax community’ of Clementsian succession (Clements 1916) has been replaced by ideas of more dynamic multiple stable and non-equilibrium states (Holling 1973; Noy-Meir 1975), thresholds (Friedel 1991), and states and transitions models (Westoby et al . -
Sir Bryn Terfel Premieres John Rutter's 'Joseph's Carol', Dedicated to the Oxford Vaccine Team in Celebratory Concert Fr
Sir Bryn Terfel premieres John Rutter’s ‘Joseph’s Carol’, dedicated to the Oxford vaccine team in celebratory concert from the Oxford Philharmonic Orchestra Friday 18 December 2020, 18:30 Streamed on Oxford Philharmonic Orchestra’s YouTube Channel: bit.ly/OPOVaccineTribute Elgar Chanson de Matin William Henry Monk Abide with Me Rodgers & Hammerstein You’ll Never Walk Alone John Rutter Joseph’s Carol WORLD PREMIERE John Rutter Look to the Day Handel Hallelujah Chorus Sir Bryn Terfel bass-baritone Oxford Philharmonic Orchestra Maxim Vengerov violin Choir of Merton College, Oxford John Rutter conductor Alexandra Lowe soprano Marios Papadopoulos conductor Alexander Olleson treble John Suchet presenter In recognition of the formidable work accomplished by the team of scientists at the University of Oxford on their Covid-19 vaccine, the Oxford Philharmonic Orchestra will stream a celebratory concert on Friday 18 December, recorded in the city’s historic Sheldonian Theatre. Performed by bass-baritone Sir Bryn Terfel, the short concert features the premiere of John Rutter’s Joseph’s Carol, written in tribute to the Oxford Vaccine Group, the Jenner Institute and the RECOVERY team. The words by John Rutter recount the long and weary journey of Joseph and Mary to Bethlehem before the birth of the baby Jesus, echoing the programme’s journey from struggle through to hope. Bryn Terfel also joins the Orchestra and the Choir of Merton College, Oxford, in a rousing programme from Rodgers & Hammerstein’s You’ll Never Walk Alone (with Jette Parker Young Artist Alexandra Lowe) to Handel’s Hallelujah Chorus. Sir Bryn and the Orchestra are also joined in the hymn of comfort, Abide with Me, by chorister Alexander Olleson of Christ Church Cathedral Choir, the recent winner of BBC Young Chorister Of The Year 2020. -
Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein
Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein By Rachel Elizabeth Owen A thesis submitted for the degree of Doctor of Philosophy at the University of London September 2003 The Edward Jenner Institute for Vaccine Research University College London ProQuest Number: U642330 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U642330 Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Hepatitis C virus establishes a persistent infection in approximately 80% of infected individuals. It is unclear why the immune system is frequently unable to mediate a response capable of controlling HCV replication. Dendritic cells (DCs) may be an extrahepatic site of viral replication and it is hypothesised that expression of the core protein within DCs may impair their functions resulting in inadequate immune responses. To investigate potential immunomodulatory effects of the core protein on DCs, replication-deficient adenoviral vectors co-expressing different versions of the core protein (full-length, truncated and a version lacking residues 125-144) with GFP were constructed. Whilst these adenoviruses were being generated, experiments were carried out with an adenoviral vector expressing all the HCV structural proteins (Ad- CE1E2). -
Soil Gaseous Emissions and Partial C and N Balances of Small-Scale Farmer Fields in a River Oasis of Western Mongolia
sustainability Article Soil Gaseous Emissions and Partial C and N Balances of Small-Scale Farmer Fields in a River Oasis of Western Mongolia Greta Jordan 1, Sven Goenster-Jordan 1,* , Baigal Ulziisuren 2 and Andreas Buerkert 1 1 Organic Plant Production and Agroecosystems Research in the Tropics and Subtropics, Universität Kassel, Steinstr. 19, 37123 Witzenhausen, Germany; [email protected] (G.J.); [email protected] (A.B.) 2 Biology Department, School of Arts and Sciences, National University of Mongolia, Youth Str. 1, Baga toiruu, Ulaanbaatar 210646, Mongolia; [email protected] * Correspondence: [email protected] Received: 2 May 2019; Accepted: 13 June 2019; Published: 18 June 2019 Abstract: During the last decades, Mongolian river oases were subjected to an expansion of farmland. Such intensification triggers substantial gaseous carbon (C) and nitrogen (N) losses that may aggravate disequilibria in the soil surface balances of agricultural plots. This study aims to quantify such losses, and assess the implications of these emissions against the background of calculated partial C and N balances. To this end, CO2, NH3, and N2O soil emissions from carrot, hay, and rye plots were measured by a portable dynamic closed chamber system connected to a photoacoustic multi-gas analyzer in six farms of the Mongolian river oasis Bulgan sum center. Average C and N flux rates 1 1 1 1 1 1 1 1 (1313 g CO2-C ha− h− to 1774 g CO2-C ha− h− ; 2.4 g NH3-N ha− h− to 3.3 g NH3-N ha− h− ; 1 1 1 1 1 1 0.7 g N2O-N ha− h− to 1.1 g N2O-N ha− h− ) and cumulative emissions (3506 kg C ha− season− 1 1 1 1 1 1 to 4514 kg C ha− season− ; 7.4 kg N ha− season− to 10.9 kg N ha− season− ) were relatively low compared to those of other agroecosystems, but represented a substantial pathway of losses (86% of total C inputs; 21% of total N inputs). -
'Astrazeneca' Covid-19 Vaccine
Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices. -
Job Description and Person Specificationselection Criteria
Job title Senior Postdoctoral Scientist Division Medical Sciences Department Nuffield Department of Medicine, Jenner Institute Clinical Centre for Vaccinology and Translational Medicine Location (CCVTM), Old Road Campus, Headington, Oxford, OX3 7LE Grade 8: £41,526 - £49,553 per annum with a discretionary range Grade and salary to £54,131 per annum Hours Full time Contract type Fixed-term contract for 20 months, in the first instance Reporting to Professor Christine Rollier & Professor Cal MacLennan Vacancy reference 147960 Additional Position funded by US funding information Development of a Gonococcal Outer Membrane Vesicle Vaccine Research topic from Lead Optimization to Phase 1 Clinical Trial Principal Investigator Professor Christine Rollier & Professor Cal MacLennan / supervisor Project team Gonococcal Vaccine Group http://www.jenner.ac.uk/ Project web site Funding partner US funding 1. Gottlieb SL, et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 2020; 38: 4362-4373. 2. Micoli, F et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. PNAS 2018; Recent publications 115: 10428-33. 3. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467-478. 4. Marsay L, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect 2015; 71: 326-37. The Role The Gonococcal Vaccine Project is based at the Jenner Institute, University of Oxford, and utilizes a novel outer membrane vesicle (OMV) technology to develop a vaccine against gonorrhoea. -
AH Istory of L and U Se in M Ongolia
A H istory of L and Use in Mongolia A H istory of L and Use in Mongolia The Thirteenth Century to the Present ELIZABETH ENDICOTT A HISTORY OF LAND USE IN MONGOLIA Copyright © Elizabeth Endicott, 2012. Softcover reprint of the hardcover 1st edition 2012 978-1-137-26965-2 All rights reserved. First published in 2012 by PALGRAVE MACMILLAN® in the United States— a division of St. Martin’s Press LLC, 175 Fifth Avenue, New York, NY 10010. Where this book is distributed in the UK, Europe and the rest of the world, this is by Palgrave Macmillan, a division of Macmillan Publishers Limited, registered in England, company number 785998, of Houndmills, Basingstoke, Hampshire RG21 6XS. Palgrave Macmillan is the global academic imprint of the above companies and has companies and representatives throughout the world. Palgrave® and Macmillan® are registered trademarks in the United States, the United Kingdom, Europe and other countries. I SBN 978-1-349-44403-8 ISBN 978-1-137-26966-9 (eBook) DOI 10.1057/9781137269669 Library of Congress Cataloging-in-Publication Data. Endicott, Elizabeth. A history of land use in Mongolia : the thirteenth century to the present / Elizabeth Endicott. p. cm. Includes bibliographical references and index. 1. Land use—Mongolia—History. 2. Land use, Rural—Mongolia— History. 3. Rangelands—Mongolia—History. 4. Herders—Mongolia— History. I. Title. HD920.8.E53 2012 333.73Ј1309517—dc23 2012016618 A catalogue record of the book is available from the British Library. Design by Newgen Imaging Systems (P) Ltd., Chennai, India. First